Skip to main content
SP5007,730.99+0.72%DOW53,569.44+0.20%NASDAQ26,541.35+1.57%BTC$80,264.00+2.04%ETH$2,513.33+0.63%GOLD$4,662.00-0.04%OIL$83.64+0.13%
Smart Investors Daily
Sign InSign Up Free
EG

OTC · EGRX

Eagle Pharmaceuticals, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

$0.18

Down-$0.50 (-73.68%)

Updated Aug 27, 2026, 9:22 PM

SID Score

3.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
6.49M
P/E ratio
0.18
Dividend yield
0.00%
52-week range
— – —
Volume
200
Avg. volume
2.86K

Price performance

EGRX price history

1M range · 0 trading sessions · Daily adjusted prices

EGRX does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest EGRX news

The latest Smart Investors Daily articles mentioning EGRX.

Stock researchCompany · Overview

EGRX research

Overview

Company profile and research snapshot.

Company profile

EAGLE PHARMS INC

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
EGRX recent ratings
DateFirmRatingTarget
Aug 9, 2023Piper SandlerUnderweight—
Mar 2, 2020Cantor FitzgeraldNeutral—
Mar 22, 2019MizuhoNeutral—
Oct 31, 2018PiperJaffrayNeutral—
Sep 21, 2018Cantor FitzgeraldOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Jan 14, 2026

Eagle Pharmaceuticals Announces Divestiture of Barhemsys

WOODCLIFF LAKE, N.J., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) is pleased to announce the divestiture of the marketing authorization for Barhemsys (amisulpride) in the U.S. to LXO Group, Paris, France. Barhemsys is used for the treatment of Postoperative Nausea and Vomiting (PONV) alone or with another antiemetic in patients with or without prior prophylaxis. Approved in February 2020 and launched in the U.S. in November 2020, Barhe

businesswire.com · Dec 7, 2025

Halper Sadeh LLC Encourages Eagle Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Eagle Pharmaceuticals, Inc. (OTCPK: EGRX) breached their fiduciary duties to shareholders. If you currently own Eagle stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about yo.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By